ELDN vs. LLY

Last updated Jul 14, 2026

ELDN (Eledon Pharmaceuticals Inc) and LLY (Eli Lilly and Company) are both stocks. Both are in the Healthcare sector — ELDN in Biotechnology, LLY in Drug Manufacturers - General. Over the past 10 years, ELDN returned -41.85%/yr vs 33.00%/yr for LLY. At a 0.12 correlation, their price movements are largely independent.

Performance

ELDN vs. LLY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Eledon Pharmaceuticals Inc (ELDN) and Eli Lilly and Company (LLY). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, ELDN achieves a 155.63% return, which is significantly higher than LLY's 10.35% return. Over the past 10 years, ELDN has underperformed LLY with an annualized return of -41.85%, while LLY has yielded a comparatively higher 33.00% annualized return.

ELDN

• 1D: 0.26%
• 1M: 8.12%
• 6M: 102.09%
• YTD: 155.63%
• 1Y: 12.87%
• 3Y*: 38.91%
• 5Y*: -12.51%
• 10Y*: -41.85%

LLY

• 1D: -0.56%
• 1M: 4.31%
• 6M: 9.70%
• YTD: 10.35%
• 1Y: 50.09%
• 3Y*: 39.01%
• 5Y*: 39.28%
• 10Y*: 33.00%

*Multi-year figures are annualized to reflect compound growth (CAGR)

ELDN vs. LLY - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
ELDN Eledon Pharmaceuticals Inc	155.63%	-63.35%	128.89%	-21.05%	-48.30%	-71.36%	47.51%	-63.75%	-60.59%	-53.87%
LLY Eli Lilly and Company	10.35%	40.25%	33.30%	60.91%	34.26%	66.08%	31.04%	16.14%	40.45%	17.83%

Correlation

The correlation between ELDN and LLY is 0.19, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.19
Correlation (3Y) Calculated over the trailing 3-year period	0.14
Correlation (5Y) Calculated over the trailing 5-year period	0.10
Correlation (10Y) Calculated over the trailing 10-year period	0.09
Correlation (All Time) Calculated using the full available price history since Sep 17, 2014	0.12

Fundamentals

Market Cap ELDN : $231.40M LLY : $1.12T
EPS ELDN : -$0.88 LLY : $28.16
PB Ratio ELDN : 10.18 LLY : 33.94
Total Revenue (TTM) ELDN : $0.00 LLY : $72.25B
Gross Profit (TTM) ELDN : $0.00 LLY : $59.75B
EBITDA (TTM) ELDN : -$84.86M LLY : $32.97B

Return for Risk

ELDN vs. LLY — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ELDN

ELDN Risk / Return Rank: 54
ELDN Sharpe Ratio Rank: 51
ELDN Sortino Ratio Rank: 56
ELDN Omega Ratio Rank: 61
ELDN Calmar Ratio Rank: 50
ELDN Martin Ratio Rank: 50

LLY

LLY Risk / Return Rank: 80
LLY Sharpe Ratio Rank: 82
LLY Sortino Ratio Rank: 78
LLY Omega Ratio Rank: 79
LLY Calmar Ratio Rank: 80
LLY Martin Ratio Rank: 81

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ELDN vs. LLY - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Eledon Pharmaceuticals Inc (ELDN) and Eli Lilly and Company (LLY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	ELDN	LLY	Difference
Sharpe ratio: Return per unit of total volatility	0.14	1.30	-1.16
Sortino ratio: Return per unit of downside risk	0.86	1.90	-1.04
Omega ratio: Gain probability vs. loss probability	1.14	1.25	-0.11
Calmar ratio: Return relative to maximum drawdown	0.19	2.17	-1.98
Martin ratio: Return relative to average drawdown	0.34	5.42	-5.08

ELDN vs. LLY - Sharpe Ratio Comparison

The current ELDN Sharpe Ratio is 0.14, which is lower than the LLY Sharpe Ratio of 1.30. The chart below compares the historical Sharpe Ratios of ELDN and LLY, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

ELDN vs. LLY - Drawdown Comparison

The maximum ELDN drawdown since its inception was -99.97%, which is greater than LLY's maximum drawdown of -68.24%. Use the drawdown chart below to compare losses from any high point for ELDN and LLY.

Drawdown Indicators

	ELDN	LLY	Difference
Max Drawdown Largest peak-to-trough decline	-99.97%	-68.24%	-31.73%
Max Drawdown (1Y) Largest decline over 1 year	-68.12%	-23.18%	-44.94%
Max Drawdown (3Y) Largest decline over 3 years	-73.77%	-34.48%	-39.29%
Max Drawdown (5Y) Largest decline over 5 years	-86.76%	-34.48%	-52.28%
Max Drawdown (10Y) Largest decline over 10 years	-99.87%	-34.48%	-65.39%
Current Drawdown Current decline from peak	-99.90%	-4.35%	-95.55%
Average Drawdown Average peak-to-trough decline	-92.04%	-19.18%	-72.86%
Ulcer Index Depth and duration of drawdowns from previous peaks	37.63%	9.27%	+28.36%

Volatility

ELDN vs. LLY - Volatility Comparison

Eledon Pharmaceuticals Inc (ELDN) has a higher volatility of 17.94% compared to Eli Lilly and Company (LLY) at 9.92%. This indicates that ELDN's price experiences larger fluctuations and is considered to be riskier than LLY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	ELDN	LLY	Difference
Volatility (1M) Calculated over the trailing 1-month period	17.94%	9.92%	+8.02%
Volatility (6M) Calculated over the trailing 6-month period	46.37%	27.56%	+18.81%
Volatility (1Y) Calculated over the trailing 1-year period	89.85%	38.79%	+51.06%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	78.52%	32.53%	+45.99%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	110.19%	30.30%	+79.89%

Dividends

ELDN vs. LLY - Dividend Comparison

ELDN has not paid dividends to shareholders, while LLY's dividend yield for the trailing twelve months is around 0.55%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
ELDN Eledon Pharmaceuticals Inc	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
LLY Eli Lilly and Company	0.55%	0.56%	0.67%	0.78%	1.07%	1.23%	1.75%	1.96%	1.94%	2.46%	2.77%	2.37%

Financials

Frequently Asked Questions

Can I hold both ELDN and LLY in my portfolio?

ELDN and LLY have a correlation of 0.19, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, ELDN or LLY?

ELDN has higher volatility (17.94%) compared to LLY (9.92%). In terms of maximum drawdown, ELDN dropped -99.97% vs LLY's -68.24%.

Which has better risk-adjusted returns?

LLY currently has the higher Sharpe Ratio (1.30 vs 0.14), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.